JP2005516035A - Ｉ型糖尿病の処置に用いる医薬の製造のための、メラガトランの使用 - Google Patents

Ｉ型糖尿病の処置に用いる医薬の製造のための、メラガトランの使用 Download PDF

Info

Publication number
JP2005516035A
JP2005516035A JP2003561625A JP2003561625A JP2005516035A JP 2005516035 A JP2005516035 A JP 2005516035A JP 2003561625 A JP2003561625 A JP 2003561625A JP 2003561625 A JP2003561625 A JP 2003561625A JP 2005516035 A JP2005516035 A JP 2005516035A
Authority
JP
Japan
Prior art keywords
melagatran
pharma
cells
acceptable derivative
islets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003561625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516035A5 (enExample
Inventor
コルスグレン，オーレ
ニルソン，ボー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2005516035A publication Critical patent/JP2005516035A/ja
Publication of JP2005516035A5 publication Critical patent/JP2005516035A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003561625A 2002-01-23 2003-01-21 Ｉ型糖尿病の処置に用いる医薬の製造のための、メラガトランの使用 Pending JP2005516035A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200198A SE0200198D0 (sv) 2002-01-23 2002-01-23 New use
PCT/SE2003/000087 WO2003061682A1 (en) 2002-01-23 2003-01-21 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus

Publications (2)

Publication Number Publication Date
JP2005516035A true JP2005516035A (ja) 2005-06-02
JP2005516035A5 JP2005516035A5 (enExample) 2006-03-09

Family

ID=20286751

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003561625A Pending JP2005516035A (ja) 2002-01-23 2003-01-21 Ｉ型糖尿病の処置に用いる医薬の製造のための、メラガトランの使用

Country Status (14)

Country Link
US (2) US7045502B2 (enExample)
EP (1) EP1469874A1 (enExample)
JP (1) JP2005516035A (enExample)
KR (1) KR20040075096A (enExample)
CN (1) CN100430089C (enExample)
BR (1) BR0306798A (enExample)
CA (1) CA2472241A1 (enExample)
IL (1) IL162853A0 (enExample)
MX (1) MXPA04007192A (enExample)
NO (1) NO20043483L (enExample)
NZ (1) NZ533749A (enExample)
SE (1) SE0200198D0 (enExample)
WO (1) WO2003061682A1 (enExample)
ZA (1) ZA200405342B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use
CN110269856A (zh) 2010-03-30 2019-09-24 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
RU2678830C2 (ru) 2013-03-15 2019-02-04 Версеон Корпорейшн Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз
KR20150130405A (ko) 2013-03-15 2015-11-23 베르선 코포레이션 트롬빈의 억제제로서의 할로게노피라졸
JP2017528486A (ja) 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
HK1246164A1 (zh) 2015-02-27 2018-09-07 Verseon Corporation 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
IL280078B2 (en) 2018-07-13 2024-04-01 Verseon Int Corporation Thrombin inhibitors, formulations, and uses thereof
EP4384193A2 (en) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
IL315000A (en) 2022-02-17 2024-10-01 Sana Biotechnology Inc Engineered cd47 proteins and uses thereof
WO2024229302A1 (en) 2023-05-03 2024-11-07 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
WO2025043172A1 (en) 2023-08-23 2025-02-27 Sana Biotechnology, Inc. Modified cd47 proteins and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
TWI238827B (en) 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9900070D0 (sv) * 1999-01-13 1999-01-13 Astra Ab New use
SE523817C2 (sv) 1999-02-05 2004-05-18 Corline Systems Ab Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use

Also Published As

Publication number Publication date
EP1469874A1 (en) 2004-10-27
BR0306798A (pt) 2004-12-07
SE0200198D0 (sv) 2002-01-23
WO2003061682A1 (en) 2003-07-31
US20060148720A1 (en) 2006-07-06
US7045502B2 (en) 2006-05-16
IL162853A0 (en) 2005-11-20
NO20043483L (no) 2004-08-20
KR20040075096A (ko) 2004-08-26
CN100430089C (zh) 2008-11-05
CA2472241A1 (en) 2003-07-31
MXPA04007192A (es) 2004-10-29
CN1729010A (zh) 2006-02-01
NZ533749A (en) 2006-02-24
ZA200405342B (en) 2005-09-28
US20050090424A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
Ozmen et al. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation
Nijhoff et al. Glycemic stability through islet-after-kidney transplantation using an alemtuzumab-based induction regimen and long-term triple-maintenance immunosuppression
Johansson et al. Low molecular weight dextran sulfate: a strong candidate drug to block IBMIR in clinical islet transplantation
Davin et al. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation
CA2481184A1 (en) Medicament for preventing and/or treating chronic rejection
US7045502B2 (en) Use of melagatran for the manufacture of a medicament for the treatment of Type 1 diabetes mellitus
Citro et al. CCL2/MCP-1 and CXCL12/SDF-1 blockade by L-aptamers improve pancreatic islet engraftment and survival in mouse
KR100828807B1 (ko) 새로운 용도의 덱스트란 설페이트
JP2007504167A (ja) 抗組織因子抗体を用いる移植片の生存を向上する方法
Vasanthan et al. Periodontal treatment considerations for cell transplant and organ transplant patients.
RU2450052C2 (ru) Способ получения бета-клеток поджелудочных желез кроликов и композиция для стимуляции выработки собственного инсулина у пациента
EP1486507A1 (en) Transmembrane nfat inhibitory peptide
RU2315621C2 (ru) Применение ингибитора или антагониста тканевого фактора
CN114762725B (zh) 一种治疗糖尿病的方法
CN114762697B (zh) 用于治疗糖尿病的药物及方法
AU2003202192A1 (en) The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus
Yoshimatsu et al. The impact of allogenic blood transfusion on the outcomes of total pancreatectomy with islet autotransplantation
Chen et al. Platelet glycoprotein VI-dependent thrombus stabilization is essential for the intraportal engraftment of pancreatic islets
Mineo et al. Islet and pancreas transplantation
RU2758536C1 (ru) Способ снижения воспалительной гиперактивации нейтрофилов
Mattke Targeting Toll-Like Receptor 4 Related Inflammation Using Small Molecule, TAK-242, to Attenuate Inflammatory Damage in Pancreatitis and Islet Transplantation
WO2022143905A1 (zh) 一种治疗糖尿病的药物及其方法
Barra Suppressing Islet Graft Rejection with Antioxidant-Based Encapsulation Materials
McCall Enhancing engraftment of islets of Langerhans and other cellular therapies for diabetes
Smetanka et al. Islet Cell Transplantation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090303

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090803